Submit your comments on this article |
Science & Technology |
Pfizer Rolls Out New Multibillion-Dollar RSV Vax |
2023-03-12 |
U.S. drugmaker Pfizer is ready to launch its respiratory syncytial virus (RSV) vaccine for both older adults and pregnant women in the United States and Europe later this year, executives said on Thursday. "Pending regulators’ approval" — haha! As if there is any doubt about which way the FDA’s decision will go, as if the agency is anything more than a ceremonial rubber-stamping formality. Is Pfizer’s new concoction medically necessary, strictly speaking, or perhaps are there alternate motives at play? |
Posted by:Besoeker |
#2 What could possible go wrong? Hey, Pfizer - thanks for thinking of us- but I'll pass... |
Posted by: Warthog 2023-03-12 10:21 |
#1 RSV? Whazzat? Wikpedia sez - RSV is the single most common cause of respiratory hospitalization in infants, and reinfection remains common in later life: it is a notable pathogen in all age groups. Infection rates are typically higher during the cold winter months, causing bronchiolitis in infants, common colds in adults, and more serious respiratory illnesses such as pneumonia in the elderly and immunocompromised. Most children will experience at least one RSV infection by age 2. Reinfection with RSV remains common throughout life. Reinfection in adulthood often produces only mild to moderate symptoms indistinguishable from the common cold or sinus infection. So a vaccine for some common colds, but you won't be sure if your vax worked or you caught the other kind. Wotta deal for Pfizer! |
Posted by: Bobby 2023-03-12 09:02 |